Krishna Institute of Medical Sciences Ltd(KIMS)

NSE: KIMSBSE: 543308

₹ 664-0.84%refreshed 23 Oct, 03:30 pm ISTMarket cap: ₹ 27,888 crWebsite: www.kimshospitals.comUpdated: 24 Oct 2026

About

Krishna Institute of Medical Sciences (KIMS) is one of India's largest corporate healthcare groups, operating multi-specialty hospitals across Telangana, Andhra Pradesh, Maharashtra, Kerala and Karnataka. As of FY26, the group had 6,464 beds (excluding O&M) across its owned and leased network and reported revenue of ₹3,904.6 Cr. KIMS runs the largest and most active thoracic organ transplant centre in India, having performed over 766 heart and double lung transplants.^[1][2]

Cluster operations and capacity

Telangana cluster (Secunderabad, Kondapur, Begumpet, Gachibowli, Asian Transcare, MIPPL): revenue ₹22,420 Mn, EBITDA ₹6,820 Mn, EBITDA margin 30.4% in FY26.^[1]
Andhra Pradesh cluster: ten hospitals, revenue ₹9,496 Mn, EBITDA ₹2,337 Mn, EBITDA margin 24.6% in FY26.^[1]
Maharashtra cluster (Nagpur, Nashik, Thane): revenue ₹4,654 Mn, occupancy 52.1% in FY26 vs 33.0% in FY25.^[1]
Kerala cluster (Kannur, Kollam, Palakkad): occupancy improved from 25.2% to 39.8%; EBITDA turned positive at ₹78 Mn in FY26 from a loss of ₹97 Mn in FY25.^[1]
Bangalore cluster: two super-specialty hospitals launched in Mahadevapura and Electronic City in FY26, together adding 800 beds, 30 operation theatres, 170+ outpatient consultation rooms and 25 Centres of Excellence.^[1]
Asset-light structures cover 859 beds under long-term leases (Kerala, Karnataka) and 850 beds under O&M partner models (Sangli, Kompally, Guntur) as of FY26.^[1]

Key operating metrics

Group bed capacity rose to 6,464 in FY26 from 5,179 in FY25, which itself was up from 3,975; group occupancy was 50.5% in FY26 vs 50.1% in FY25.^[1][3]
Consolidated ARPOB: ₹47,200 in Q1 FY27 (+9.7% YoY); ₹44,644 for full-year FY26 (+14.0% YoY).^[4]
IP volume: 72,493 in Q1 FY27 (+26.6% YoY); 2,46,297 for FY26 (+15.4% YoY). OP volume: 6,58,617 in Q1 FY27 (+28.5% YoY); 23,00,360 for FY26 (+25.4% YoY).^[4]
Occupancy: 49.0% on 5,639 operational beds in Q1 FY27, with 2,761 occupied beds (+14.0% YoY).^[4]
ALOS: 3.47 days in Q1 FY27; 3.57 days for FY26.^[4]
Telangana ARPOB: ₹77,009 in Q1 FY27 (+10.3% YoY); Bangalore ARPOB: ₹92,793 in Q1 FY27, elevated by quaternary/transplant case mix.^[4]
ARPP: ₹1,63,573 in Q1 FY27 (+6.8% YoY); ₹1,59,575 for FY26 (+11.4% YoY).^[4]

Clinical services and specialties

KIMS Hospitals offers more than 40 specialty services including Cardiac Sciences, Oncology, Neurosciences, Organ Transplantation and Maternal & Child Health.^[1]
Heart-Lung Transplant Programme under Dr Sandeep Attawar has performed over 766 heart and double lung transplants, the largest and most active thoracic organ transplant centre in India.^[1]
KIMS has completed 10,000+ successful brain tumour surgeries under Dr Manas Panigrahi.^[1]
Mahadevapura Bangalore completed 25 transplants within its first 3 months of operation, including 16 in Q3 FY26 (Liver 7, Lung 2, Renal 7).^[5]

Payor mix and customers

FY26 payor mix: Cash 53%, Insurance 30%, Corporate 12%, Aarogyasri (government scheme) 5%.^[1]
No single customer accounts for 10% or more of group revenue, given a large and unrelated customer base.^[1]

Doctor engagement and workforce

Doctors invest directly in the equity of their respective sub-entities under a doctor equity participation model; doctor attrition was 22.64% in FY26.^[1]
As of 31 March 2026, the group employed over 10,000 personnel with a total workforce of 23,400+ clinical and non-clinical staff.^[1]

Expansion and capex pipeline

Infrastructure expenditure reached ₹7,583 million in FY26.^[1]
New 787-bed Kondapur hospital admitted its first patient on 20 June 2026; management targets ₹1,200 Cr annual revenue over 4 - 5 years.^[4]
Palakkad (Kerala, 208 beds) commissioned in April 2026, taking Kerala presence to three units; secured Transplant Licence in May 2026.^[4]
Thrissur (Kerala) O&M hospital (351 beds) expected to commence within 3 - 4 months from August 2026.^[4]
Residual FY27 capex of ₹100 - 125 Cr planned across Secunderabad, Rajahmundry and Kondapur.^[4]
Chennai greenfield hospital (300 beds) planned under a 26-year land agreement, targeting Q4 FY29.^[5]
1 - 2 brownfield acquisitions being shortlisted in Kerala, Telangana and Maharashtra; no definitive timeline as of Q1 FY27.^[4]

Recent developments

On 6 October 2026, KIMS agreed to acquire up to 51% equity in Sarvottam Health Care Private Limited for up to ₹80 Cr; completion expected on or before 31 October 2026.^[6]
KIMS raised ₹1,500 Cr via a QIP and approved a ₹600 Cr preferential allotment to promoters; ₹1,100 Cr of QIP proceeds used to retire debt, reducing gross debt from ₹3,250 Cr to ~₹2,400 Cr.^[4]
O&M agreements signed with Golden Lan Solutions (~300-bed facility near Kondapur, Telangana) and Sarvottam Healthcare (Kakinada, AP); losses will not flow through KIMS P&L during the O&M phase.^[4]
Mahadevapura Bangalore reached EBITDA breakeven in less than 7 months from commissioning (June 2026); Electronic City Bangalore expected to break even by end of FY27.^[4]
AP cluster saw a ~one-month near-complete Aarogyasri suspension in Q3 FY26 due to a government payment dispute; volumes reverted to Q2 FY26 levels in January 2026.^[5]

Accreditations and research

KIMS holds NABH, NABL, AACI and ISO accreditations across its hospital network.^[1]
KIMS Foundation and Research Centre, established in 2010, researches biotechnology, genomics, pharmacology and medical engineering with the University of Hyderabad, IICT and Genome Foundation.^[1]

Market Cap

₹27,888 Cr

High / Low

₹858 / 576

Stock P/E

131.2

Price / Book

11.8

Book Value

₹56

EPS

₹6.0

No. of Shares

40.01 Cr

ROCE

9.1%

ROE

11.0%

OPM

13.9%

Debt / Equity

1.44

Sales

₹3,905 Cr

Net Profit

₹242 Cr

Promoter holding

32.5%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials